109098-70-6

Basic information

• Product Name: ethyl 4-amino-2-bromobenzoate
• CAS NO: 109098-70-6
• Molecular Formula: C₉H₁₀BrNO₂
• Molecular Weight: 244.0852
• Mol File: 109098-70-6.mol

Chemical Properties

• Boiling Point: 355.346°C at 760 mmHg
• Flash Point: 168.708°C
• Density: 1.504g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.588
• CAS DataBase Reference: ethyl 4-amino-2-bromobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-amino-2-bromobenzoate(109098-70-6)
• EPA Substance Registry System: ethyl 4-amino-2-bromobenzoate(109098-70-6)

Safety Data

• Hazardous Substances Data: 109098-70-6(Hazardous Substances Data)

Upstream product

• 64-17-5 ethanol 
• 2486-52-4 2-bromo-4-aminobenzoic acid 
• 7745-93-9 2-bromo-4-nitrotoluene 
• 16426-64-5 2-bromo-4-nitrobenzoic acid 
• 128566-93-8 2-bromo-4-nitrobenzoic acid ethyl ester 

Downstream Products

• 1057076-38-6 C₂₃H₂₄BrF₃N₂O₄ 

Relevant articles and documents

2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS

The present invention relates to Nav1.8 Inhibitor 2,3-dihydroquinazolin compounds of Formula (X); wherein Y', X', B', R1', R2', R3', R5', R6', R7', and z1 are as defined herein; or pharmaceutically acceptable salts or tautomer forms thereof, corresponding pharmaceutical compositions or formulations, methods or processes of compound preparation, methods, compounds for use in, uses for and/or combination therapies for treating pain and/or pain-related or associated disease(s), disorder(s) or condition(s), respectively.

IMIDAZOQUINOLINE COMPOUNDS AS BROMODOMAIN INHIBITORS

The present invention provides compound of formula (I), or an isotopic form, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, N-oxide or S-oxide thereof; and processes for their preparation. The invention further relates to pharmaceutical compositions containing said compounds and their use in the treatment of diseases or disorders mediated by bromodomain containing proteins, particularly cancer.

THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS

The present invention relates to novel LXR ligands of Formula (I) and pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

Therapeutic compounds for treating dyslipidemic conditions

The present invention relates to novel LXR ligands of Formula I and pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thichroman and 1,2,3,4-tetrahydroquinolinecarboxlic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity

Compounds of the formula wherein the symbols have the meaning defined in the specification have retinoid-like biological activity.